Literature DB >> 9513522

[The oxygen transporting capability of neo red cells (NRC) evaluated under total cardiopulmonary bypass].

Y Izumi1, T Yamahata, R Yozu, K Kobayashi, M Mukai.   

Abstract

The oxygen transporting capability of an artificial oxygen carrier NRC was evaluated by employing it as a perfusate for total cardiopulmonary bypass. NRC is a type of liposome encapsulated hemoglobin. It has a particle size of approximately 220 nm, with a hemoglobin concentration of 5.6 g/dl and its P50 is controlled to 45 Torr. Male beagles were used in the experiment. Approximately 80% of the estimated circulatory volume was exchanged with NRC and total cardiopulmonary bypass was initiated. Arterial oxygen tension and carbon dioxide tension were controlled to 400 Torr and 40 Torr respectively. The perfused we heated to 37 degrees C. The rate of flow was altered during the experiment. Oxygen consumption reached a plateau at 9.3 ml/kg/min where oxygen delivery was 14.9 ml/kg/min. At this point the oxygen consumed per gram of hemoglobin from NRC was equivalent to that from dog red blood cells. This indicated that almost an equal amount of oxygen was consumed from NRC in comparison to red blood cells. Regarding oxygen transporting capability, NRC could be considered a candidate for perfusate in cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513522     DOI: 10.1007/bf03217719

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

Review 1.  Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: an overview.

Authors:  T M Chang
Journal:  Biomater Artif Cells Immobilization Biotechnol       Date:  1992

2.  Characterization of neo red cells (NRCs), their function and safety in vivo tests.

Authors:  A Takahashi
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  1995

3.  Characteristics of neo red cells, their function and safety: in vivo studies.

Authors:  Y Ogata; H Goto; K Sakaguchi; M Suzuki; K Ohsaki; K Suzuki; A R Saniabadi; T Kamitani; A Takahashi
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  1994

4.  Mixed venous oxygen saturation. Its role in the assessment of the critically ill patient.

Authors:  G Kandel; A Aberman
Journal:  Arch Intern Med       Date:  1983-07

5.  Tissue oxygenation in clinical medicine: an historical review.

Authors:  M J Miller
Journal:  Anesth Analg       Date:  1982-06       Impact factor: 5.108

6.  A human recombinant haemoglobin designed for use as a blood substitute.

Authors:  D Looker; D Abbott-Brown; P Cozart; S Durfee; S Hoffman; A J Mathews; J Miller-Roehrich; S Shoemaker; S Trimble; G Fermi
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

7.  Oxygen transport and oxygen consumption in critically ill patients.

Authors:  J Villar; A S Slutsky; E Hew; A Aberman
Journal:  Chest       Date:  1990-09       Impact factor: 9.410

8.  Physiologic responses to exchange transfusion with hemoglobin vesicles as an artificial oxygen carrier in anesthetized rats: changes in mean arterial pressure and renal cortical tissue oxygen tension.

Authors:  Y Izumi; H Sakai; K Hamada; S Takeoka; T Yamahata; R Kato; H Nishide; E Tsuchida; K Kobayashi
Journal:  Crit Care Med       Date:  1996-11       Impact factor: 7.598

9.  Synthetic erythrocytes from lipid encapsulated hemoglobin.

Authors:  L Djordjevich; I F Miller
Journal:  Exp Hematol       Date:  1980-05       Impact factor: 3.084

Review 10.  Current status of injectable oxygen carriers.

Authors:  T F Zuck; J G Riess
Journal:  Crit Rev Clin Lab Sci       Date:  1994       Impact factor: 6.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.